Femasys Inc.

FEMY • Medical - Instruments & Supplies

$2.98

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$9.97M

Crecimiento

-5.0%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.8Liquidez saludable · 4.53Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 16 ago 2026, 12:20 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$2.98

Change0.00%

Shares Out3.34M

Market Cap$9.97M

Enterprise Value$13.31M

52W Range2.19 - 22.20

Beta-2.09

P/E-0.85

P/S4.33

P/B2.47

P/FCF-0.55

EV/Sales5.79

Price$2.98

Change0.00%

Shares Out3.34M

Market Cap$9.97M

Enterprise Value$13.31M

52W Range2.19 - 22.20

Beta-2.09

P/E-0.85

P/S4.33

P/B2.47

P/FCF-0.55

EV/Sales5.79

EV/EBITDA-0.87

EV/FCF-0.73

Earnings Yield-118.07%

FCF Yield-182.36%

Dividend Yield0.00%

Gross Margin61.96%

Oper. Margin-7.67%

Profit Margin-8.12%

Debt/Eq0.80

Current Ratio4.53

Quick Ratio2.95

Revenue 5Y-5.02%

Volume107.48K

Avg Volume83.71K

EPS Surprise0.07

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

71/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

46/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.8Liquidez saludable · 4.53Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

FEMY

Analyst sentiment

Based on 6 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 6/18/2021

Industria: Medical - Instruments & Supplies

P/B i: 2.47

Deuda / Patrimonio i: 0.80

Margen operativo: -766.95%

Margen neto: -812.27%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: 0.80

Ratio corriente: 4.53

Ratio rápido: 2.95

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Lee-Sepsick Kathy

Transacción: 08/07/2026

COMPRA

Cambio

+15,625

Precio

$2.95

Presentación

08/11/2026

Tipo

COMPRA

Lee-Sepsick Kathy

Transacción: 08/07/2026

COMPRA

Cambio

+15,625

Precio

$2.95

Presentación

08/11/2026

Tipo

COMPRA

Lee-Sepsick Kathy

Transacción: 08/07/2026

COMPRA

Cambio

+15,625

Precio

$3.20

Presentación

08/11/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Lee-Sepsick Kathy	COMPRA	+15,625	$2.95	08/07/2026	08/11/2026
Lee-Sepsick Kathy	COMPRA	+15,625	$2.95	08/07/2026	08/11/2026
Lee-Sepsick Kathy	COMPRA	+15,625	$3.20	08/07/2026	08/11/2026
Elefant Dov	COMPRA	+15,625	$2.95	08/07/2026	08/11/2026
Elefant Dov	COMPRA	+15,625	$3.20	08/07/2026	08/11/2026
Elefant Dov	COMPRA	+15,625	$2.95	08/07/2026	08/11/2026
Canning John Charles	COMPRA	+4,375	$2.95	08/07/2026	08/11/2026
Canning John Charles	COMPRA	+4,375	$2.95	08/07/2026	08/11/2026
Canning John Charles	COMPRA	+4,375	$3.20	08/07/2026	08/11/2026
Sipos Jeremy Alexander	COMPRA	+3,125	$2.95	08/07/2026	08/11/2026
Sipos Jeremy Alexander	COMPRA	+3,125	$2.95	08/07/2026	08/11/2026
Sipos Jeremy Alexander	COMPRA	+3,125	$3.20	08/07/2026	08/11/2026
Mifek Jeffrey Gerald	COMPRA	+3,125	$2.95	08/07/2026	08/11/2026
Mifek Jeffrey Gerald	COMPRA	+3,125	$2.95	08/07/2026	08/11/2026
Mifek Jeffrey Gerald	COMPRA	+3,125	$3.20	08/07/2026	08/11/2026
Mifek Jeffrey Gerald	OTRO	0	Not reported	07/06/2026	08/11/2026
Mifek Jeffrey Gerald	COMPRA	+6,250	$4.08	07/06/2026	08/11/2026
Larsen Charles	COMPRA	+880	$3.67	06/24/2026	08/11/2026
Milnes Alistair	COMPRA	+880	$3.67	06/24/2026	08/11/2026
Uzialko Edward R	COMPRA	+880	$3.67	06/24/2026	08/11/2026

Sobre la compañía

Femasys Inc.

Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.

Fuente - Link

Competidores

AIMD APLM BCTX COCH CRIS DARE EKSO HBIO PCSA VVOS

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue ® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to introduce its female and male fertility diagnostics, FemVue and SpermVue™, together with FemaSeed Complete, an in-office intratubal insemination solution designed as a first-line fertility treatment, within UNC Health OB/GYN practice locations. “We launched our OB/GYN commercial initiative at the ACOG Annual Clinical & Scientific Meeting on May 1st with the goal of bringing fertility evaluation and treatment earlier in the care pathway, and we are thrilled that a leading academic health system such as UNC Health is making these important technologies available within its OB/GYN practices,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys.

GlobeNewsWire

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

The U.S. Food and Drug Administration (FDA) on Wednesday authorized the modular premarket approval application pathway for FemBloc, a non-surgical permanent birth control technology.

Benzinga

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.

GlobeNewsWire

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents

-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the issuance of patents in the United States and key international markets that expand intellectual property protection for the blended polymer component of FemBloc, the Company's non-surgical permanent birth control technology. These patents broaden and extend FemBloc's global intellectual property protection, complementing existing patents covering its delivery system and further strengthening the technology's competitive position in a highly regulated market with rigorous clinical and regulatory requirements.

GlobeNewsWire

Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

-- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has entered into a securities purchase agreement (the “Purchase Agreement”) for a $30 million private placement with certain accredited investors. The financing was led by new institutional investor Nantahala Capital, with participation from additional new healthcare-focused funds, including Rosalind Advisors, Inc., as well as members of Femasys' management team. The private placement is subject to customary closing conditions and is expected to close on or around August 10, 2026.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-08	-0.06667	0.0049	0.07157
2026-03-31	-0.08333	-0.01	0.07333
2025-11-14	-0.115	-0.1	0.015
2025-08-08	-0.18	-0.16	0.02
2025-05-08	-0.17	-0.23	-0.06
2025-03-27	-0.25	-0.23	0.02
2024-11-12	-0.2	-0.24	-0.04
2024-08-08	-0.18	-0.21	-0.03
2024-05-09	-0.22	-0.17	0.05
2024-03-28	-0.19	-0.19	0
2023-11-14	-0.25	-0.26	-0.01
2023-08-10	-0.19	-0.22	-0.03